Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
  • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
  • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
  • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4196—1,2,4-Triazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
  • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4245—Oxadiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
  • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/10—Antioedematous agents; Diuretics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
  • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

• the Mineralocorticoid Receptor is a nuclear hormone receptor that is activated by aldosterone and regulates the expression of many genes involved in electrolyte homeostasis and cardiovascular disease. Increased circulating aldosterone increases blood pressure through its effects on natriuresis, with potentially additional effects on the brain, heart and vasculature.
• hyperaldosteronism have been linked to many pathophysiological processes resulting in renal and cardiovascular disease. While hyperaldosteronism is commonly caused by aldosterone-producing adenomas, resistant hypertensive patients frequently suffer from increased aldosterone levels often termed as "Aldosterone Breakthrough" as a result of increases in serum potassium or residual AT1R activity. Hyperaldosteronism and aldosterone breakthrough typically results in increased MR activity and MR antagonists have been shown to be effective as anti-hypertensive agents and also in the treatment of heart failure and primary hyperaldosteronism.
• MR MR regulates sodium retention, potassium excretion and water balance in response to aldosterone.
• MR expression in the brain also appears to play a role in the control of neuronal excitability, in the negative feedback regulation of the hypothalamic-pituitary-adrenal axis, and in the cognitive aspects of behavioral performance ( Castren et al., J. of Neuroendocrinology, 3, 461-66 (1993 )).
• Eplerenone and spironolactone are two MR antagonists that have been shown to be efficacious in treating cardiovascular disease, particularly hypertension and heart failure (RALES Investigators (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure, N. Engl. J. Med., 1999, 341(10):709-717 ; Pitt B, et al., EPHESUS investigator (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N. Engl. J. Med., 348(14):1309-1321 ; Funder JW., (2010) Eplerenone in chronic renal disease: the EVALUATE trial, Hypertens.
• aldosterone antagonists are useful in the treatment of subjects suffering from one or more cognitive dysfunctions including, but not limited to psychoses, cognitive disorders (such as memory disturbances), mood disorders (such as depression and bipolar disorder), anxiety disorders and personality disorders.
• Elevation in aldosterone levels, or excess stimulation of mineralocorticoid receptors is linked to several physiological disorders or pathologic disease states, including Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, and disorders associated with excess catecholamine levels.
• Conn's Syndrome primary and secondary hyperaldosteronism
• increased sodium retention increased magnesium and potassium excretion (diuresis)
• diuresis increased water retention
• hypertension isolated systolic and combined systolic/diastolic
• arrhythmias myocardial fibrosis
• myocardial infarction Bartter's Syndrome
• Bartter's Syndrome disorders associated with excess
• This invention addresses those needs by providing compounds, compositions and methods for the treatment or prevention of hypertension, heart failure, other cardiovascular disorders and other aldosterone disorders.
• the present invention relates to compounds which have Mineralocorticoid Receptor (MR) antagonist activity, which are valuable pharmaceutically active compounds for the therapy and prophylaxis of diseases, for example for treating aldosterone-mediated disorders, including cardiovascular disease.
• MR Mineralocorticoid Receptor
• the present invention is directed to compounds of the Formula I or pharmaceutically acceptable salts thereof.
• the invention furthermore relates to compounds of Formula I for use in treating and preventing the above mentioned diseases and to processes for preparing compounds of the Formula I and for pharmaceutical preparations which comprise compounds of Formula I.
• the invention concerns compounds of Formula I: or pharmaceutically acceptable salts thereof, wherein
• alkyl, cycloalkyl, alkenyl and alkynyl is optionally substituted with one to three groups selected from R 12 ;
• R 3 is phenyl wherein said phenyl is optionally substituted with one to three R 9 ;
• R 4 is
• R x is independently H or halo.
• RY is H and all other variables are as previously defined in Formula I.
• R2 is C 1 -C 6 alkyl.
• R 3 is phenyl, wherein said phenyl is optionally substituted with one to three halo, OR.
• R 4 is: -NR 6 S(O) 2 R 8 .
• the instant invention is related to a compound of Formula I, as illustrated by Formula II: or a pharmaceutically acceptable salt thereof, wherein:
• the invention is a compound which is IUPAC Name methyl (4-chlorophenyl)(4-nitro-1 H -indol-1-yl)acetate methyl (2-chloro-4-fluorophenyl)(4-nitro-1 H- indol-1-yl)acetate methyl (2,4-dichlorophenyl)(4-nitro-1 H -indol-1-yl)acetate methyl (3-bromophenyl)(4-nitro-1 H -indol-1-yl)acetate methyl (4-methoxyphenyl)(4-nitro-1 H -indol-1-yl)acetate methyl (2-chloro-4-fluorophenyl)(1 H -indol-1-yl)acetate methyl (2-chloro-4-fluorophenyl)(4-cyano-1 H -indol-1-yl)acetate ethyl 1-[1-(2-chloro
• the invention is a compound which is:
• the invention is a compound which is:
• alkyl is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
• the term “cycloalkyl” means carbocycles containing no heteroatoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, decahydronaphthyl and the like.
• Commonly used abbreviations for alkyl groups are used throughout the specification, e.g. methyl may be represented by conventional abbreviations including "Me" or CH 3 or a symbol that is an extended bond without defined terminal group, e.g.
• C 1-6 alkyl (or “C 1 -C 6 alkyl”) for example, means linear or branched chain alkyl groups, including all isomers, having the specified number of carbon atoms.
• C 1-6 alkyl includes all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
• C 1-4 alkyl means n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. If no number is specified, 1-10 carbon atoms are intended for linear or branched alkyl groups.
• a substituted butyl group (C 4 alkyl) could have 1, 2 or 3 substituents on one, two, three or four of the carbon atoms of the butyl group.
• the group “CF 3 " for example, is a methyl group having three fluorine atoms attached the same carbon atom.
• alkenyl unless otherwise indicated, means carbon chains which contain at least one carbon-carbon double bond, and which may be linear or branched or combinations thereof. Examples of alkenyl include, but are not limited to, vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.
• cycloalkenyl means carbocycles containing no heteroatoms having at least one carbon-carbon double bond.
• alkynyl refers to a hydrocarbon radical straight, branched or cyclic, containing from 2 to 10 carbon atoms and at least one carbon to carbon triple bond. Up to three carbon-carbon triple bonds may be present.
• C 2 -C 6 alkynyl means an alkynyl radical having from 2 to 6 carbon atoms.
• Alkynyl groups include ethynyl, propynyl, butynyl, 3-methylbutynyl and so on.
• the straight, branched or cyclic portion of the alkynyl group may contain triple bonds and may be substituted if a substituted alkynyl group is indicated.
• Aryl unless otherwise indicated, means mono- and bicyclic aromatic rings containing 6-12 carbon atoms. Examples of aryl include, but are not limited to, phenyl, naphthyl, indenyl and the like. “Aryl” also includes monocyclic rings fused to an aryl group. Examples include tetrahydronaphthyl, indanyl and the like. The preferred aryl is phenyl.
• Heteroaryl unless otherwise indicated, means a mono- or bicyclic aromatic ring or ring system having 5 to 10 atoms and containing at least one heteroatom selected from O, S and N, . Examples include, but are not limited to, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, pyridinyl,oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyrimidinyl, pyridazinyl, pyrazinyl, and the like.
• Heteroaryl also includes aromatic heterocyclic groups fused to heterocycles that are non-aromatic or partially aromatic, and aromatic heterocyclic groups fused to cycloalkyl rings. Additional examples of heteroaryls include, but are not limited to, dihydrofuranyl, indazolyl, thienopyrazolyl, imidazopyridazinyl, pyrazolopyrazolyl, pyrazolopyridinyl, imidazopyridinyl and imidazothiazolyl. Heteroaryl also includes such groups in charged form, e.g., pyridinium.
• Heterocyclyl unless otherwise indicated, means a 4-, 5- or 6-membered monocyclic saturated ring containing at least one heteroatom selected from N, S and O, in which the point of attachment may be carbon or nitrogen.
• heterocyclyl include, but are not limited to, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, imidazolidinyl, 2,3-dihydrofuro(2,3-b)pyridyl, benzoxazinyl, and the like.
• the term also includes partially unsaturated monocyclic rings that are not aromatic, such as 2- or 4-pyridones attached through the nitrogen or N- substituted-(1 H , 3 H )-pyrimidine-2, 4-diones ( N -substituted uracils).
• Heterocyclyl moreover includes such moieties in charged form, e.g., piperidinium.
• Halogen or halo
• fluorine fluoro
• chlorine chloro
• bromine bromine
• iodine iodo
• halo is fluorine or chlorine.
• substitution by a named substituent is permitted on any atom in a ring (e.g., aryl, a heteroaryl ring, or a saturated heterocyclic ring) provided such ring substitution is chemically allowed and results in a stable compound.
• a “stable” compound is a compound which can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic or prophylactic administration to a subject).
• Reference to the compounds of structural Formula I includes the compounds of other generic structural Formulae that fall within the scope of Formula I, including but not limited to Formula II, Formula III and/or Formula IV.
• any variable e.g., R, R a , R x , etc.
• its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
• substituted shall be deemed to include multiple degrees of substitution by a named substituent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the (two or more) substituents can be the same or different.
• Compounds of structural Formula I may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereoisomeric mixtures and individual diastereoisomers.
• the present invention is meant to comprehend all such isomeric forms of the compounds of structural Formula I.
• Compounds of structural Formula I may be separated into their individual diastereoisomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof, or via chiral chromatography using an optically active stationary phase.
• Absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.
• any stereoisomer or isomers of a compound of the general structural Formula I may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known absolute configuration.
• racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated.
• the separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereoisomeric mixture, followed by separation of the individual diastereoisomers by standard methods, such as fractional crystallization or chromatography.
• the coupling reaction is often the formation of salts using an enantiomerically pure acid or base.
• the diasteromeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue.
• the racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art.
• Some of the compounds described herein may exist as tautomers which have different points of attachment of hydrogen accompanied by one or more double bond shifts.
• a ketone and its enol form are keto-enol tautomers.
• the individual tautomers as well as mixtures thereof are encompassed with compounds of the present invention.
• the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominately found in nature.
• the present invention is meant to include all suitable isotopic variations of the compounds of structural Formula I.
• different isotopic forms of hydrogen (H) include protium ( 1 H) and deuterium ( 2 H, also denoted as D).
• Protium is the predominant hydrogen isotope found in nature.
• Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
• Isotopically-enriched compounds within structural Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
• the present invention includes all stereoisomeric forms of the compounds of the Formula I. Centers of asymmetry that are present in the compounds of Formula I can all independently of one another have S configuration or R configuration.
• the invention includes all possible enantiomers and diastereomers and mixtures of two or more stereoisomers, for example mixtures of enantiomers and/or diastereomers, in all ratios.
• enantiomers are a subject of the invention in enantiomerically pure form, both as levorotatory and as dextrorotatory antipodes, in the form of racemates and in the form of mixtures of the two enantiomers in all ratios.
• the invention includes both the cis form and the trans form as well as mixtures of these forms in all ratios.
• the preparation of individual stereoisomers can be carried out, if desired, by separation of a mixture by customary methods, for example by chromatography or crystallization, by the use of stereochemically uniform starting materials for the synthesis or by stereoselective synthesis.
• a derivatization can be carried out before a separation of stereoisomers.
• the separation of a mixture of stereoisomers can be carried out at the stage of the compounds of the Formula I or at the stage of an intermediate during the synthesis.
• the present invention also includes all tautomeric forms of the compounds of Formula I.
• the present invention includes all atropisomer forms of the compounds of Formula I.
• Atropisomers are stereoisomers resulting from hindered rotation about single bonds where the steric strain barrier to rotation is high enough to allow for the isolation of the conformers.
• Atropisomers display axial chirality. Separation of atropisomers is possibly by chiral resolution methods such as selective crystallization.
• references to the compounds of structural Formula I are meant to also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they are used as precursors to the free compounds or their pharmaceutically acceptable salts or in other synthetic manipulations.
• the compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt.
• pharmaceutically acceptable salt refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts of basic compounds encompassed within the term “pharmaceutically acceptable salt” refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
• Representative salts of basic compounds of the present invention include, but are not limited to, the following: acetate, ascorbate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, camphorate, camphorsulfonate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, methanes
• suitable pharmaceutically acceptable salts thereof include, but are not limited to, salts derived from inorganic bases including aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, mangamous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
• Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, cyclic amines, dicyclohexyl amines and basic ion-exchange resins, such as arginine, betaine, caffeine, choline, N,N -dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N -ethylmorpholine, N -ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
• basic ion-exchange resins such
• esters of carboxylic acid derivatives such as methyl, ethyl, or pivaloyloxymethyl
• acyl derivatives of alcohols such as O -acetyl, O -pivaloyl, O -benzoyl, and O -aminoacyl
• esters and acyl groups known in the art for modifying the solubility or hydrolysis characteristics for use as sustained-release or prodrug formulations are described.
• Solvates including but not limited to the ethyl acetate solvate, and in particular, the hydrates of the compounds of structural Formula I are included in the present invention as well.
• the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). Salts can be obtained from the compounds of Formula I by customary methods which are known to the person skilled in the art, for example by combination with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange from other salts.
• the present invention also includes all salts of the compounds of Formula I which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of physiologically acceptable salts.
• physiologically acceptable salt(s) and “pharmaceutically acceptable salt(s)” are intended to have the same meaning and are used interchangeably herein.
• the present invention also describes processes for the preparation of the compounds of the Formula I which are described in the following and by which the compounds of the invention are obtainable.
• the compounds of the Formula I according to the invention competitively antagonize the mineralocortoid receptor (MR) and they are therefore useful agents for the therapy and prophylaxis of disorders related to increased aldosterone levels.
• MR mineralocortoid receptor
• the ability for the compounds of the Formula I to antagonize MR can be examined, for example, in the activity assay described below.
• One aspect of the invention that is of interest relates to a compound in accordance with formula I or a pharmaceutically acceptable salt thereof for use in the treatment of the human or animal body by therapy.
• Another aspect of the invention that is of interest relates to a compound in accordance with formula I or a pharmaceutically acceptable salt thereof for use as an anti-hypertensive agent in a human or animal.
• Another aspect of the invention that is of interest is a compound in accordance with Formual I or a pharmaceutically acceptable salt thereof for use in treating cardiovascular disease, heart failure, hypertension, atherosclerosis, primary hyperaldosternoism or a related condition in a human patient in need of such treatment.
• Another aspect of the invention that is of interest relates to a compound of Formula I or a pharmaceutically acceptable salt thereof for use in treating metabolic syndrome in a mammal.
• Another aspect of the invention that is of interest relates to a compound of Formula I or a pharmaceutically acceptable salt thereof for use in treating a physiological or pathologic disease, selected from including Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, and disorders associated with excess catecholamine levels in a human patient.
• a physiological or pathologic disease selected from including Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bar
• Another aspect of the invention that is of interest is a compound of Formula I or a pharmaceutically acceptable salt thereof for use in treating renal failure in a human patient.
• Another aspect of the invention that is of interest is a compound of Formula I or a pharmaceutically acceptable salt thereof for use in treating hypertension, including, but not limited to, essential hypertension, resistant hypertension, systolic hypertension, pulmonary arterial hypertension, and the like.
• Another aspect of the invention is a compound of Formula I or a pharmaceutically acceptable salt thereof for use in treating hypertension in an obese animal or human.
• Another aspect of the invention is a compound of Formula I or a pharmaceutically acceptable salt thereof for use in treating hypertension in a diabetic animal or human.
• the compounds of the Formula I and their pharmaceutically acceptable salts can be administered to animals, preferably to mammals, and in particular to humans, as pharmaceuticals by themselves, in mixtures with one another or in the form of pharmaceutical preparations.
• the term "patient” includes animals, preferably mammals and especially humans, who use the instant active agents for the prevention or treatment of a medical condition. Administering of the drug to the patient includes both self-administration and administration to the patient by another person.
• the patient may be in need of treatment for an existing disease or medical condition, or may desire prophylactic treatment to prevent or reduce the risk of said disease or medical condition.
• a subject of the present invention therefore also are the compounds of the Formula I and their pharmaceutically acceptable salts for use as pharmaceuticals, their use for antagonizing mineralocorticoid receptors and in particular their use in the therapy and prophylaxis of the abovementioned syndromes as well as their use for preparing medicaments for these purposes.
• terapéuticaally effective (or efficacious) amount and similar descriptions such as “an amount efficacious for treatment” are intended to mean that amount of a pharmaceutical drug that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
• prophylactically effective (or efficacious) amount and similar descriptions such as “an amount efficacious for prevention” are intended to mean that amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician.
• the dosage regimen utilizing a compound of the instant invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the potency of the compound chosen to be administered; the route of administration; and the renal and hepatic function of the patient.
• a consideration of these factors is well within the purview of the ordinarily skilled clinician for the purpose of determining the therapeutically effective or prophylactically effective dosage amount needed to prevent, counter, or arrest the progress of the condition. It is understood that a specific daily dosage amount can simultaneously be both a therapeutically effective amount, e.g., for treatment of hypertension, and a prophylactically effective amount, e.g., for prevention of myocardial infarction.
• a subject of the present invention are pharmaceutical preparations (or pharmaceutical compositions) which comprise as active component an effective dose of at least one compound of the Formula I and/or a pharmaceutically acceptable salt thereof and a customary pharmaceutically acceptable carrier, i.e., one or more pharmaceutically acceptable carrier substances and/or additives.
• a subject of the invention are, for example, said compound and its physiologically or pharmaceutically acceptable salts for use as a pharmaceutical, pharmaceutical preparations which comprise as active component an effective dose of said compound and/or a physiologically (or pharmaceutically) acceptable salt thereof and a customary pharmaceutically acceptable carrier, and the uses of said compound and/or a physiologically (or pharmaceutically) acceptable salt thereof in the therapy or prophylaxis of the abovementioned syndromes as well as their use for preparing medicaments for these purposes.
• the pharmaceuticals according to the invention can be administered orally, for example in the form of pills, tablets, lacquered tablets, sugar-coated tablets, granules, hard and soft gelatin capsules, aqueous, alcoholic or oily solutions, syrups, emulsions or suspensions, or rectally, for example in the form of suppositories. Administration can also be carried out parenterally, for example subcutaneously, intramuscularly or intravenously in the form of solutions for injection or infusion.
• Suitable administration forms are, for example, percutaneous or topical administration, for example in the form of ointments, tinctures, sprays or transdermal therapeutic systems, or the inhalative administration in the form of nasal sprays or aerosol mixtures, or, for example, microcapsules, implants or rods.
• the preferred administration form depends, for example, on the disease to be treated and on its severity.
• the amount of active compound of the Formula I and/or its physiologically (or pharmaceutically) acceptable salts in the pharmaceutical preparations normally is from 0.2 to 700 mg, preferably from 1 to 500 mg, per dose, but depending on the type of the pharmaceutical preparation it can also be higher.
• the pharmaceutical preparations usually comprise 0.5 to 90 percent by weight of the compounds of the Formula I and/or their physiologically (or pharmaceutically) acceptable salts.
• the preparation of the pharmaceutical preparations can be carried out in a manner known per se.
• one or more compounds of the Formula I and/or their pharmaceutically acceptable salts together with one or more solid or liquid pharmaceutical carrier substances and/or additives (or auxiliary substances) and, if desired, in combination with other pharmaceutically active compounds having therapeutic or prophylactic action, are brought into a suitable administration form or dosage form which can then be used as a pharmaceutical in human or veterinary medicine.
• Carriers for soft gelatin capsules and suppositories are, for example, fats, waxes, semisolid and liquid polyols, natural or hardened oils, etc.
• Suitable carriers for the preparation of solutions, for example of solutions for injection, or of emulsions or syrups are, for example, water, physiologically sodium chloride solution, alcohols such as ethanol, glycerol, polyols, sucrose, invert sugar, glucose, mannitol, vegetable oils, etc.
• Suitable carriers for microcapsules, implants or rods are, for example, copolymers of glycolic acid and lactic acid.
• the pharmaceutical preparations can also contain customary additives, for example fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants.
• customary additives for example fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants.
• the dosage of the active compound of the Formula I to be administered and/or of a pharmaceutically acceptable salt thereof depends on the individual case and is, as is customary, to be adapted to the individual circumstances to achieve an optimum effect. Thus, it depends on the nature and the severity of the disorder to be treated, and also on the sex, age, weight and individual responsiveness of the human or animal to be treated, on the efficacy and duration of action of the compounds used, on whether the therapy is acute or chronic or prophylactic, or on whether other active compounds are administered in addition to compounds of the Formula I.
• a daily dose of approximately 0.01 to 100 mg/kg, preferably 0.01 to 10 mg/kg, in particular 0.3 to 5 mg/kg (in each case mg per kg of bodyweight) is appropriate for administration to an adult weighing approximately 75 kg in order to obtain the desired results.
• the daily dose can be administered in a single dose or, in particular when larger amounts are administered, be divided into several, for example two, three or four individual doses. In some cases, depending on the individual response, it may be necessary to deviate upwards or downwards from the given daily dose.
• the compounds of the Formula I bind to the mineralocorticoid receptor and antagonize the biological effects of aldosterone and cortisol.
• They can also be employed as a scientific tool or as aid for biochemical investigations in which such an effect on the mineralocorticoid receptor is intended, and also for diagnostic purposes, for example in the in vitro diagnosis of cell samples or tissue samples.
• the compounds of the Formula I and salts thereof can furthermore be employed, as already mentioned above, as intermediates for the preparation of other pharmaceutically active compounds.
• One or more additional pharmacologically active agents may be administered in combination with a compound of Formula I.
• An additional active agent (or agents) is intended to mean a pharmaceutically active agent (or agents) different from the compound of Formula I.
• any suitable additional active agent or agents including anti-hypertensive agents, anti-atherosclerotic agents such as a lipid modifying compound, anti-diabetic agents and/or anti-obesity agents may be used in any combination with the compound of Formula I in a single dosage formulation (a fixed dose drug combination), or may be administered to the patient in one or more separate dosage formulations which allows for concurrent or sequential administration of the active agents (co-administration of the separate active agents).
• angiotensin converting enzyme inhibitors e.g, alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltipril, perindopril, quinapril, ramipril, spirapril, temocapril, or trandolapril), angiotensin II receptor antagonists (e.g., losartan, valsartan, candesartan, olmesartan, telmesartan) neutral endopeptidase inhibitors (e.g., thiorphan
• urea derivatives of di- and tri-peptides See U.S. Pat. No. 5,116,835 ), amino acids and derivatives ( U.S. Patents 5,095,119 and 5,104,869 ), amino acid chains linked by non-peptidic bonds ( U.S. Patent 5,114,937 ), di- and tri-peptide derivatives ( U.S. Patent 5,106,835 ), peptidyl amino diols ( U.S. Patents 5,063,208 and 4,845,079 ) and peptidyl beta-aminoacyl aminodiol carbamates ( U.S. Patent 5,089,471 ); also, a variety of other peptide analogs as disclosed in the following U.S.
• Patent 4,980,283 and fluoro- and chloro-derivatives of statone-containing peptides ( U.S. Patent 5,066,643 ), enalkrein, RO 42-5892, A 65317, CP 80794, ES 1005, ES 8891, SQ 34017, aliskiren (2(S),4(S),5(S),7(S)- N -(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)-phenyl]-octanamid hemifumarate) SPP600, SPP630 and SPP635), endothelin receptor antagonists, vasodilators, calcium channel blockers (e.g., amlodipine, nifedipine, verastrial, diltiazem, gallopamil, niludipin
• hydralazine lipid lowering agents (e.g., niacin, HMG Co-A reductase inhibitors), metabolic altering agents including insulin sensitizing agents and related compounds (e.g., muraglitazar, glipizide, metformin, rosiglitazone) or with other drugs beneficial for the prevention or the treatment of the above-mentioned diseases including nitroprusside and diazoxide.
• lipid lowering agents e.g., niacin, HMG Co-A reductase inhibitors
• metabolic altering agents including insulin sensitizing agents and related compounds (e.g., muraglitazar, glipizide, metformin, rosiglitazone) or with other drugs beneficial for the prevention or the treatment of the above-mentioned diseases including nitroprusside and diazoxide.
• Examples of other active ingredients that may be administered in combination with a compound of Formula I, and either administered separately or in the same pharmaceutical composition include:
• additional active agents may be administered with the compounds described herein.
• the additional active agent or agents can be lipid modifying compounds or agents having other pharmaceutical activities, or agents that have both lipid-modifying effects and other pharmaceutical activities.
• additional active agents which may be employed include but are not limited to HMG-CoA reductase inhibitors, which include statins in their lactonized or dihydroxy open acid forms and pharmaceutically acceptable salts and esters thereof, including but not limited to lovastatin (see US Patent No. 4,342,767 ), simvastatin (see US Patent No. 4,444,784 ), dihydroxy open-acid simvastatin, particularly the ammonium or calcium salts thereof, pravastatin, particularly the sodium salt thereof (see US Patent No.
• HMG-CoA synthase inhibitors include squalene epoxidase inhibitors; squalene synthetase inhibitors (also known as squalene synthase inhibitors), acylcoenzyme A: cholesterol acyltransferase (ACAT) inhibitors including selective inhibitors of ACAT-1 or ACAT-2 as well as dual inhibitors of ACAT-1 and -2; microsomal triglyceride transfer protein (MTP) inhibitors; endothelial lipase inhibitors; bile acid sequestrants; LDL receptor inducers; platelet aggregation inhibitors, for example glycoprotein IIb/IIIa fibrinogen receptor antagonists and aspirin; human peroxisome proliferator activated receptor gamma (PPAR-gamma) agonists including the compounds commonly referred to as glitazones for example pioglitazone and rosiglitazone and, including those compounds included within the structural class known as
• Reaction scheme A illustrates a method of synthesis of compounds of type 2.
• a phenylacetic acid derivative of type 1 is treated with a bromine source, such as N- bromosuccinimide or the like, in the presence of a suitable initiator, such as AIBN, to afford an ⁇ -bromophenylacetate of type 2.
• a suitable initiator such as AIBN
• the reaction is run in an inert solvent, such as carbon tetrachloride or benzene, at elevated temperatures between 70 0C and the boiling temperature of the solvent.
• Reaction scheme B illustrates a method of synthesis of compounds of type 4.
• a substituted indole or indazole of type 3 is treated with a suitable base, such as sodium hydride in examples involving substituted indoles or cesium carbonate in examples involving substituted indazoles, followed by reaction with electrophiles, such as ⁇ -bromophenylacetates of type 2, to afford compounds of type 4.
• the reaction is performed in a polar aprotic solvent, such as DMF or DMSO, at temperatures between 0 0C and room temperature.
• the product is a compound of type 4, which can be elaborated to compounds of the present invention (I) as described in the subsequent schemes.
• compound 4a is treated with a suitable catalyst, such as Pt/C (Pd/C can be utilized when compound 4a does not contain additional reactive functionality such as halogen substitution), under a hydrogen atmosphere (balloon pressure) in a suitable solvent, such as ethyl acetate or the like, to afford an aminoindole of type 5.
• a suitable catalyst such as Pt/C (Pd/C can be utilized when compound 4a does not contain additional reactive functionality such as halogen substitution)
• a suitable solvent such as ethyl acetate or the like
• the nitro group can be reduced by treating compounds of type 4a with tin(II)chloride in the presence of strong acid, such as concentrated HCl or sulfuric acid, in a protic solvent, such as ethanol or the like, at elevated temperatures between 50 0C and the boiling temperature of the solvent.
• strong acid such as concentrated HCl or sulfuric acid
• a protic solvent such as ethanol or the like
• the products of type 5 can be treated with ditertbutyl dicarbonate under basic conditions, such as reaction conditions known as Schotten-Baumen conditions.
• the product is a compound of type 6, which can be elaborated to compounds of the present invention (I) as described in the subsequent schemes.
• Reaction scheme D illustrates a method of synthesis of compounds of type 8.
• substrates of type 6 are treated with a suitable base, such as sodium hydride, followed by reaction of the corresponding anion with electrophiles of type 7 to afford the desired product.
• a suitable base such as sodium hydride
• Most conditions involve slow addition of solutions of 6 to a mixture containing the base prior to addition of the electrophile ( 7 ).
• the reaction is run in a polar aprotic solvent, such as DMF or the like, at temperatures between -20 0C and 0 0C, and the product of the reaction is a compound of type 8, which can be elaborated to compounds of the present invention (I) as described in the subsequent schemes.
• Reaction scheme E illustrates a method of synthesis of compounds of type 9.
• compounds of type 8 are first treated under strongly acidic conditions, such as trifluoroacetic acid or concentrated HCl, to yield aminoindoles or aminoindazoles of type 5a, which are subsequently reacted with a suitable electrophile source, such as a sulfonyl chloride or an acyl halide or acyl anhydride, in the presence of a suitable base, such as 4-methylmorpholine or diisopropylethylamine or the like.
• a suitable electrophile source such as a sulfonyl chloride or an acyl halide or acyl anhydride
• a suitable base such as 4-methylmorpholine or diisopropylethylamine or the like.
• the product of the reaction is a compound of type 9, which can be elaborated to compounds of the present invention (I) as described in the subsequent schemes.
• Reaction scheme F illustrates a method of synthesis of compounds of structural formula 12 via an organotransition metal catalyzed cross-coupling reaction commonly referred to as the Suzuki reaction.
• an aryl- or heteroaryl-compound of type 10 is reacted with a boronic acid ( 11 ) or boronate ( 12 ) coupling partner in the presence of a suitable palladium catalyst, such as [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) or tetrakistriphenylphosphinepalladium(0) or the like, and a base such as aqueous sodium carbonate or aqueous tribasic sodium phosphate or the like ( Pure Appl.
• a suitable palladium catalyst such as [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) or tetrakistriphenylphosphinepalladium(0) or the
• Reaction scheme G illustrates a method of synthesis of compounds of structural formula 15 following methods similar to those previously described in Scheme F.
• Compounds of type 15 that are derived from inputs of type 14 that contain additional functional groups can be elaborated to furnish other compounds of the present invention (I).
• Reaction scheme H illustrates a method of synthesis of compounds of structural formula 17.
• compounds of type 16 can be hydrolyzed to carboxylic acids of type 17 using a variety of methods known to those skilled in organic synthesis.
• the product carboxylic acid of structural formula 17 can be used in a variety of methods known in organic synthesis to afford compounds of the present invention (I).
• Reaction scheme I illustrates the method of synthesis of compounds of structural formula 20 .
• compounds of type 18 are treated with an amine of type 19 to afford an amide of type 20.
• the amide bond coupling reaction illustrated in reaction scheme I is conducted in an appropriate inert solvent such as DMF, DCM or the like and may be performed with a variety of reagents suitable for amide coupling reactions such as HATU, EDC or PyBOP.
• reagents suitable for amide coupling reactions such as HATU, EDC or PyBOP.
• Conditions for the amide bond coupling reaction shown in reaction Scheme I are known to those skilled in organic synthesis. Such modifications may include, but are not limited to, the use of basic reagents such as triethylamine, DIPEA, or NMM, or the addition of an additive such as HOAt or HOBt.
• reaction Scheme I is usually conducted at a temperatures between 0 °C and room temperature, occasionally at elevated temperatures, and the coupling reaction is conducted for periods of 1 to 24 hours.
• the product of the reaction is a compound of type 20, which can be elaborated to furnish other compounds of the present invention (I) as described in subsequent schemes.
• Reaction scheme J illustrates a method for the synthesis of compounds of type 22.
• a primary amide of type 21 is treated with a dehydrating reagent, such as cyanuric chloride or the like, to generate a nitrile of type 22.
• the reaction is performed in an inert solvent, such as DCM or DMF, between 0 0C and room temperature.
• the product of the reaction is a compound of type 22, which can be elaborated to furnish other compounds of the present invention (I) as described in subsequent schemes.
• Scheme K illustrates in the most generalized manner how compounds of type 23 can be elaborated to a variety of heterocyclic derivatives of structural formula 24 using known methods in organic synthesis. Specific examples of such transformations are shown in the Examples section.
• Scheme L illustrates a method for the synthesis of compounds of type 26.
• an ester of type 25 is treated with a strong reducing agent, such as lithium borohydride or lithium aluminum hydride or the like, in an etheral solvent, such as THF or diethyl ether, between 0 0C and room temperature.
• a strong reducing agent such as lithium borohydride or lithium aluminum hydride or the like
• an etheral solvent such as THF or diethyl ether
• Scheme M illustrates a method for the synthesis of compounds of type 28.
• a cyanoester of type 27 is treated with an excess of reducing agent, such as sodium borohydride, in the presence of an inorganic accelerating agent, such as cobalt(II)chloride, to afford an amine intermediate (not shown) that undergoes intramolecular cyclization onto the ester moiety to yield a lactam of type 28.
• reducing agent such as sodium borohydride
• an inorganic accelerating agent such as cobalt(II)chloride
• Scheme N illustrates the method for the resolution of a racemic compound of structural formula 29 in which the asterisked carbon is a center of chirality.
• the latter, or intermediates en route to their preparation may be resolved to afford enantiomerically pure compounds such as 30 and 31 by chiral stationary phase liquid chromatography techniques or other suitable methods known in organic synthesis.
• Methyl 2-chloro-4-fluorophenylacetate (3.15 g, 15.6 mmol), N -bromosuccinimide (2.77 g, 15.6 mmol) and AIBN (255 mg, 1.56 mmol) were suspended in benzene (50.0 mL) and degassed via N 2 stream. The resulting mixture was heated to 80 0C for 12 h. After cooling to rt, the mixture was partially concentrated in vacuo and partitioned between ether and water. The layers were separated, and the organic layer was washed with water and brine. The organics were dried (MgSO 4 ) filtered and concentrated in vacuo.
• Table i-1 Cpds. i-1 A Cpds. i-1 A a f b g c h d i e Table i-1. 1 H NMR and parent Ion m / z (MH) + data for compounds.
• Step A Preparation of methyl (4-chlorophenyl)(4-nitro-1 H -indol-1-yl)acetate (1)
• Step A Preparation of methyl (4-amino-1 H -indol-1-yl)(4-chlorophenyl)acetate (2a)
• Step B Preparation of methyl ⁇ 4-[( tert -butoxycarbonyl)amino]-1 H -indol-1-yl ⁇ (4-chlorophenyl)acetate (2b)
• Step C Preparation of methyl (4-chlorophenyl) ⁇ 4-[(methylsulfonyl)amino]-1 H -indol-1-yl ⁇ acetate (17)
• Methanesulfonyl chloride (159 ⁇ L, 2.04 mmol) was added to a stirred solution of 2b (320 mg, 1.02 mmol) and triethylamine (213 ⁇ L, 1.53 mmol) in DCM (3 mL) at rt. After 1 h, the reaction mixture was poured into water and extracted with DCM. The combined organics were washed with brine, dried (Na 2 SO 4 ), filtered and concentrated in vacuo.
• Step A Preparation of methyl 2- ⁇ 4-[( tert- butoxycarbonyl)amino]-1 H -indol-1-yl ⁇ -2-(4-chlorophenyl)butanoate (3a)
• Step B Preparation of methyl 2-(4-amino-1 H -indol-1-yl)-2-(4-chlorophenyl)butanoate (3b)
• Trifluoroacetic acid (37.5 mL, 487 mmol) was added rapidly dropwise to a stirred solution of 3a (8.62 g, 19.5 mmol) in DCM (100 mL) at 0 0C. After 1h, the reaction was quenched by careful addition of saturated aqueous sodium bicarbonate, followed by NaHCO 3 (s) and extracted with ether. The organics were washed with saturated aqueous sodium bicarbonate, dried (MgSO 4 ), filtered and concentrated in vacuo to afford the title compound 3b. m / z (ES) 343 (MH) + .
• Step C Preparation of methyl 2-(4-chlorophenyl)-2- ⁇ 4-[(methylsulfonyl)amino]-1 H -indol-1-yl ⁇ butanoate (25)
• Methanesulfonyl chloride (1.59 mL, 20.4 mmol) was added to a stirred solution of 3b (6.67 g, 19.5 mmol) and 4-methylmorpholine (2.78 mL, 25.3 mmol) in DCM (100 mL) at 0 0C. After 30 min, an additional portion of methanesulfonyl chloride (0.80 mL, 10.2 mmol) was added. After 1 h, the reaction mixture was partitioned between DCM and saturated aqueous ammonium chloride. The layers were separated and the aqueous layer was extracted with DCM. The combined organics were washed with brine, dried (Na 2 SO 4 ), filtered and concentrated in vacuo.
• Enantiomers 25a and 25b were separated using preparative normal phase chiral HPLC.
• a solution of 25 in MeOH/acetonitrile was injected onto a CHIRALCEL ® AS-H (available from Chiral Technologies, Inc., Exton, Pa.) semi-preparative (250 ⁇ 30 mm) HPLC column (eluting with 45% [(2:1) MeOH:acetonitrile]/CO 2 with a column temperature of 35 0C at 70 mL/min with UV detection at 220 nm).
• the enantiomers were separated with the faster eluting enantiomer 25a having a retention time of 2.61 min and the slower eluting enantiomer 25b having a retention time of 3.13 min, with the retention times derived from injection onto an analytical CHIRALCEL ® AS-H HPLC column (4.6 x 250 mm, 2.1 mL/min, 40% [(2:1) MeOH:acetonitrile]/CO 2 , 35 0C).
• the separated fractions were concentrated to provide the enantiomers 25a and 25b .
• the faster eluting (R)-enantiomer 25a is preferred for making final products.
• Step A Preparation of (R)-2-(4-chlorophenyl)-2- ⁇ 4-[(methylsulfonyl)amino]-1 H -indol-1-yl ⁇ butanoic acid (4a)
• Step B Preparation of ( R )-2-(4-chlorophenyl)- N -methyl-2- ⁇ 4-[(methylsulfonyl)amino]-1 H- indol-1-yl ⁇ butanamide (39)
• Step A Preparation of ( R )- N- ⁇ 1-[1-(4-chlorophenyl)-1-cyanopropyl]-1 H -indol-4-yl ⁇ methanesulfonamide (5a)
• Step B Preparation of ( R )-(1 E )-2-(4-chlorophenyl)- N' -hydroxy-2- ⁇ 4-[(methylsulfonyl)amino]-1 H -indol-1-yl ⁇ butanimidamide (5b)
• Step C Preparation of ( R )-methyl N - ⁇ 1-[1-(4-chlorophenyl)-1-(5-methyl-1,2,4-oxadiazol-3-yl)propyl]-1 H -indol-4-yl ⁇ methanesulfonamide (57)
• Step A Preparation of (4-chlorophenyl) ⁇ 4-[(methylsulfonyl)amino]-1 H- indol-1-yl ⁇ acetic acid (6a)
• Compound 6a was prepared from compound 17 following procedures similar to those previously described in Example 4, step A.
• Step B Preparation of N - ⁇ 1-[(4-chlorophenyl)(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-1H-indol-4-yl ⁇ methanesulfonamide (63)
• N' -Hydroxybenzenecarboximidamide 49 mg, 0.36 mmol was added to a stirred solution of compound 6a (90 mg, 0.24 mmol), N -(3-dimethylaminopropyl)- N' -ethylcarbodiimide hydrochloride (91 mg, 0.48 mmol), 1-hydroxybenzotriazole (44 mg, 0.29 mmol) and N,N,- diisopropylethylamine (50 ⁇ L, 0.29 mmol) in DMF (2.4 mL). The reaction was allowed to stir at rt for 2h, at which time, the reaction was partitioned between ethyl acetate and water.
• Step A Preparation of ( R )-N- ⁇ 1-[1-(4-chlorophenyl)-1-(3-phenyl-1 H -1,2,4-triazol-5- yl)propyl]-1 H -indol-4-yl ⁇ methanesulfonamide (64)
• Step A Preparation of (R)- N - ⁇ 1-[1-(4-chlorophenyl)-1-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)propyl]-1 H -indol-4-yl ⁇ methanesulfonamide (67)
• Step A Preparation of 2- ⁇ 4-[( tert -butoxycarbonyl)amino]-1 H -indol-1-yl ⁇ -2-(4-chlorophenyl)butanoic acid (9a)
• Step B Preparation of tert -butyl (1- ⁇ 2-(4-chlorophenyl)-1-[(2-hydroxy-1-phenylethyl)amino]-1-oxobutan-2-yl ⁇ -1 H -indol-4-yl)carbamate (9b)
• Step C Preparation of tert -butyl ⁇ 1-[1-(4-chlorophenyl)-1-(4-phenyl-1,3-oxazol-2-yl)propyl]-1 H -indol-4-yl ⁇ carbamate (9c)
• Step D Preparation of N - ⁇ 1-[1-(4-chlorophenyl)-1-(4-phenyl-1,3-oxazol-2-yl)propyl]-1 H- indol-4-yl ⁇ methanesulfonamide (77)
• Step A Preparation of methyl (3-bromophenyl) ⁇ 4-[(methylsulfonyl)amino]-1 H -indol-1-yl ⁇ acetate (10a)
• Compound 10a was prepared by initially reacting i-li with 4-nitroindole following procedures as described in Example 1. The product of the reaction was reacted under conditions described in Example 2, step A, followed by Example 2, step C to afford the title compound 10a. m / z (ES) 437 (MH) + .
• Step B Preparation of methyl 2-(3'-methoxybiphenyl-3-yl)-2- ⁇ 4-[(methylsulfonyl)amino]-1 H- indol-1-yl ⁇ butanoate (78)
• Step A Preparation of ( R )- N - ⁇ 1-[(2 R )-2-(4-chlorophenyl)-1-hydroxybutan-2-yl]-1 H -indol-4-yl ⁇ methanesulfonamide (82)
• Lithium borohydride (15 mg, 0.713 mmol) was added to a stirred solution of 25a (200 mg, 0.475 mmol) in THF (2.4 mL) at 0 0C, and the reaction mixture was allowed to warm to rt overnight. The excess lithium borohydride was quenched by careful addition of 1M HCl, and the resulting mixture was partitioned between ethyl acetate and brine. The layers were separated, and the organic layer was dried (Na 2 SO 4 ), filtered and concentrated in vacuo.
• Enantiomers 36a and 36b were separated using preparative normal phase chiral HPLC.
• a solution of 36 in DCM/MeOH/acetonitrile was injected onto a CHIRALCEL ® OD-H (available from Chiral Technologies, Inc., Exton, Pa.) semi-preparative (250 ⁇ 30 mm) HPLC column (eluting with 40% [(2:1) MeOH:acetonitrile]/CO 2 with a column temperature of 35 0C at 70 mL/min with UV detection at 230 nm).
• the enantiomers were separated with the faster eluting enantiomer 36a having a retention time of 2.33 min and the slower eluting enantiomer 36b having a retention time of 2.93 min, with the retention times derived from injection onto an analytical CHIRALCEL ® OD-H HPLC column (4.6 x 250 mm, 2.4 mL/min, 40% [(2:1) MeOH:acetonitrile]/CO 2 , 35 0C).
• the separated fractions were concentrated to provide the enantiomers 36a and 36b. Under the separation conditions cited above, the slower eluting enantiomer 36b is preferred for making final products.
• Step A Preparation of N - ⁇ 1-[3-(4-chlorovhenyl)-2-oxopyrrolidin-3-yl]-1H-indol-4-yl ⁇ methanesulfonamide (84)
• Fuming sulphuric acid (105 mL) was added dropwise to 4-fluoro-1-methyl-2-nitrobenzene (30 g, 0.194 mol) at -5 °C ⁇ 0 °C and a mixture of fuming sulphuric acid (54 mL) and fuming nitric acid (18 mL) was added dropwise to it at -5 °C ⁇ 0 °C over the period of 3 h. After complete addition, the reaction mixture was stirred for 3 hours at ambient temperature. TLC showed complete conversion of starting material to the product. The reaction mixture was poured into ice and extracted with dichloromethane. The combined organic layers was washed with water (600 mL), sat.
• Step B 2-(4-fluoro-2,6-dinitrophenyl)- N,N- dimethylethenamine
• Step C 6-fluoro-1 H -indol-4-amine
• Step D 1-(4-chlorobenzyl)-6-fluoro-1 H -indol-4-amine
• Step E tert -butyl 1-(4-chlorobenzyl)-6-fluoro-1 H -indol-4-ylcarbamate
• Step F 2-(4-( tert -butoxycarbonylamino)-6-fluoro-1 H -indol-1-yl)-2-(4-chlorophenyl)acetic acid
• Step G methyl 2-(4-amino-6-fluoro-1 H -indol-1-yl)-2-(4-chlorophenyl)acetate
• Step H methyl 2-(4-( tert -butoxycarbonylamino)-6-fluoro-1 H -indol-1-yl)-2-(4-chlorophenyl) acetate
• Step I methyl 2-(4-( tert -butoxycarbonylamino)-6-fluoro-1 H -indol-1-yl)-2-(4- chlorophenyl)butanoate
• Step J methyl 2-(4-amino-6-fluoro-1 H -indol-1-yl)-2-(4-chlorophenyl)butanoate
• Step K methyl 2-(4-chlorophenyl)-2-(6-fluoro-4-(methylsulfonamido)-1H indol-1-yl)butanoate
• Methanesulfonyl chloride (0.23 g, 2 mmol) was added to a stirred solution of methyl 2-(4-amino-6-fluoro-1 H -indol-1-yl)-2-(4-chlorophenyl)butanoate (0.6 g, 1.7 mmol) and 4-methylmorpholine (0.25 g, 2.5 mmol) in DCM (8 mL) at 0 °C. After 30 min, an additional portion of methanesulfonyl chloride (0.1 g, 1 mmol) was added. After 1 h, the reaction mixture was partitioned between DCM and saturated aqueous ammonium chloride.
• Step L N -(1-(2-(4-chlorophenyl)-1-hydroxybutan-2-yl)-6-fluoro-1 H -indol-4-yl)methanesulfonamide (Compound 85)
• Step A tert -butyl 1-(3-(4-chlorophenyl)-2-hydroxy-2-methylpentan-3-yl)-6-fluoro-1 H -indol-4- ylcarbamate
• Step B 3-(4-amino-6-fluoro-1 H -indol-1-yl)-3-(4-chlorophenyl)-2-methylpentan-2-ol
• Step C N -(1-(3-(4-chlorophenyl)-2-hydroxy-2-methylpentan-3-yl)-6-fluoro-1 H -indol-4-yl)methanesulfonamide (Compound 90)
• Step A Methyl 2-(4-amino-1 H -indol-1-yl)-2-(4-chlorophenyl)butanoate
• Step B Methyl 2-(4-chlorophenyl)-2-(4-(2,5-dimethyl-1 H -pyrrol-1-yl)-1 H -indol-1-yl)butanoate
• Step C 2-(4-Chlorophenyl)-2-(4-(2,5-dimethyl-1 H -pyrrol-1-yl)-1 H -indol-1-yl)butan-1-ol
• Step D 1-(2-(4-Chlorophenyl)-1-methoxybutan-2-yl)-4-(2,5-dimethyl-1 H -pyrrol-1-yl)-1 H- indole
• Step E 1-(2-(4-Chlorophenyl)-1-methoxybutan-2-yl)-1 H -indol-4-amine
• Step F N -(1-(2-(4-chlorophenyl)-1-methoxybutan-2-yl)-1 H -indol-4-yl)methanesulfonamide
• Step A tert -butyl 1-(3-(4-chlorophenyl)-2-oxopentan-3-yl)-6-fluoro-1 H -indol-4-ylcarbamate
• Step B 3-(4-amino-6-fluoro-1 H -indol-1-yl)-3-(4-chlorophenyl)pentan-2-one
• Step C N -(1-(3-(4-chlorophenyl)-2-oxopentan-3-yl)-6-fluoro-1 H -indol-4-1)methanesulfonamide (Compound 98)
• Step A the mixture of methyl 2-(4-chlorophenyl)-2-(4-nitro-1 H -indazol-1-yl)acetate and methyl 2-(4-chlorophenyl)-2-(4-nitro-2 H -indazol-2-yl)acetate
• Step B methyl 2-(4-amino-1 H -indazol-1-yl)-2-(4-chlorophenyl)acetate
• Step C methyl 2-(4-( tert -butoxycarbonylamino)-1 H -indazol-1-yl)-2-(4-chlorophenyl)acetate
• step B The compound from step B (22 g, 70 mml) and (Boc) 2 O (30 g, 140 mmol) were dissolved in dioxane (260 mL). Then sat. Na 2 CO 3 aq (50 mL) was added to the mixture at 0 °C. The mixture was stirred at room temperate for 2 days. Then the solvent was removed under reduced pressure, and the residue was dissolved in EtOAc (500 mL), washed with H 2 O (100 mL), brine (100 mL).
• Step D methyl 2-(4-( tert -butoxycarbonylamino)-1 H -indazol-1-yl)-2-(4-chlorophenyl)butanoate
• Enantiomer A and enantiomer B were obtained by the below chiral separation conditions:
• Step E tert -butyl 1-(2-(4-chlorophenyl)-1-hydroxybutan-2-yl)-1 H -indazol-4-ylcarbamate
• Step F tert -butyl 1-[2-(4-chlorophenyl)-1-oxobutan-2-yl]-1 H -indazol-4-ylcarbamate
• Step G tert -butyl 1-[3-(4-chlorophenyl)-2-hydroxypentan-3-yl]-1H-indazol-4-ylcarbamate
• Step H 3-(4-amino-1 H -indazol-1-yl)-3-(4-chlorophenyl)pentan-2-ol
• step B Using the same procedure described for the preparation of Example 15, step B but replacing the tert -butyl 1-(3-(4-chlorophenyl)-2-hydroxy-2-methylpentan-3-yl)-6-fluoro-1 H- indol-4-ylcarbamate with tert -butyl 1-[2-(4-chlorophenyl)-1-oxobutan-2-yl]-1 H -indazol-4-ylcarbamate gave the title compound.
• Step I N -(1-(3-(4-chlorophenyl-2-hydroxypentan-3-yl-1 H -indazol-4-yl)methanesulfonamide
• step E replacing methyl 2-[4-( tert -butoxycarbonylamino)-1 H -indazol-1-yl]-2-(4-chlorophenyl)butanoate with methyl 2-(4-( tert -butoxycarbonylamino)-1 H -indol-1-yl)-2-(4-chlorophenyl)butanoate, methyl 2-(4-( tert- butoxycarbonylamino)-1 H -indol-1-yl)-2-(2,4-dichlorophenyl)butanoate, methyl 2-(4-( tert- butoxycarbonylamino)-6-fluoro-1 H -indol-1-yl)-2-(2,4-dichlorophenyl)butanoate, methyl 2-(4-( tert -butoxycarbonylamino)-6-fluoro-1 H -indol-1-yl)-2-(2,4-
• step E replacing methanesulfonyl chloride with methylsulfamoyl chloride and dimethylsulfamoyl chloride, compound 118 and compound 119 of Table 15 were prepared respectively.
• Compound 106 and compound 107 were obtained by the below chiral separation conditions:
• Step A methyl 2-(4-amino-1 H -indazol-1-yl)-2-(4-chlorophenyl)butanoate
• Step B methyl 2-(4-chlorophenyl)-2-(4-(methylsulfonamido)-1 H -indazol-1-yl)butanoate
• Step C methyl 2-(4-chlorophenyl)-2-(4-( N -((2-(trimethylsilyl)ethoxy)methyl)methyl sulfon amido)-1 H -indazol-1-yl)butanoate
• Step D N -(1-(2-(4-chlorophenyl)-1-hydroxybutan-2-yl)-1 H -indazol-4-yl)- N -((2-(trimethylsilyl) ethoxy)methyl)methanesulfonamide
• Step E N -(1-(2-(4-chlorophenyl)-1-oxobutan-2-yl)-1 H -indazol-4-yl)- N -((2-(trimethylsilyl) ethoxy)methyl)methanesulfonamide
• Step F ( E )- N -(1-(3-(4-chlorophenyl)-1-cyanopent-1-en-3-yl)-1 H -indazol-4-yl)- N -((2-(trimethylsilyl)ethoxy)methyl)methanesulfonamide
• Step G N -(1-(1-(4-chlorophenyl)-1-(2-cyanocyclopropyl)propyl)-1 H -indazol-4-yl)- N -((2-(trimethylsilyl)ethoxy)methyl)methanesulfonamide
• Step H N -(1-(1-(4-chlorophenyl)-1-(2-cyanocyclopropyl)propyl)-1 H -indazol-4-yl)methane sulfonamide (Compound 120)
• Step A tert -Butyl1-(2-(4-chlorophenyl)-1-hydroxybutan-2-yl)-1 H -indol-4-ylcarbamate
• Step B tert -Butyl 1-(2-(4-chlorophenyl)-1-oxobutan-2-yl)-1 H -indol-4-ylcarbamate
• Step C tert -butyl 1-(2-(4-chlorophenyl)-1-cyanobutan-2-yl)-1 H -indol-4-ylcarbamate
• Step D 3-(4-amino-1 H -indol-1-yl)-3-(4-chlorophenyl)pentanenitrile
• Step E N -(1-(2-(4-chlorophenyl)-1-cyanobulan-2-yl)-1 H -indol-4-yl)methanesulfonamide
• Step A ( E )- tert -butyl 1-(3-(4-chlorophenyl)-1-cyanopent-1-en-3-yl)-1 H -indol-4-ylcarbamate
• Step B ( E )-4-(4-amino-1 H -indol-1-yl)-4-(4-chlorophenyl)hex-2-enenitrile
• Step C ( E ) -N- (1-(3-(4-chlorophenyl)-1-cyanopent-1-en-3-yl)-1 H -indol-4-yl)methanesulfonamide
• Step A N -(1-(3-(4-chlorophenyl)-2-oxopentan-3-yl)-1 H -indol-4-yl)methanesulfonamide
• Step B N -(1-(3-(4-chlorophenyl)-1-cyano-2-hydroxy-2-methylpentan-3-yl)- 1H -indol-4-yl)methanesulfonamide
• Step C N -(1-(3-(4-Chlorophenyl)-1-cyano-2-methylpent-1-en-3-yl)-1 H -indol-4-yl)methane sulfonamide (Compound 132)
• step A Using the same procedure described for the preparation of Example 22, but in step A replacing the tert -butyl 1-(2-(4-chlorophenyl)-1-oxobutan-2-yl)-1 H -indol-4-ylcarbamate with tert -butyl 1-(2-(4-chlorophenyl)-1-oxobutan-2-yl)-1 H -indazol-4-ylcarbamate, tert -butyl 1-(2-(4-chlorophenyl)-1-oxobutan-2-yl)-6-fluoro-1 H -indazol-4-ylcarbamate gave the compound 133 and compound 134.
• Step A ( E ) -tert -butyl 1-(3-(4-chlorophenyl)-1-cyanopent-1-en-3-yl)-1 H -indazol-4-ylcarbamate
• Step B N -(1-(2-(4-chlorophenyl)-1-hydroxybutan-2-yl)-1 H -indazol-4-yl)- N -((2-(trimethylsilyl) ethoxy)methyl)methanesulfonamide
• step C Using the same procedure described for the preparation of Example 22, step C but replacing the ( E )-4-(4-amino-1 H -indol-1-yl)-4-(4-chlorophenyl)hex-2-enenitrile with ( E )-4-(4-amino-6-fluoro-1 H -indazol-1-yl)-4-(4-chlorophenyl)hex-2-enenitrile gave the compound 136.
• Step A ( E )-4-(4-amino-1 H -indazol-l-yl)-4-(4-chlorophenyl)hex-2-enenitrile
• Step B ( E ) -N -(1-(3-(4-chlorophenyl)-1-cyanopent-1-en-3-yl)-1 H -indazol-4-yl)methane sulfonamide
• Step C N -(1-(3-(4-chlorophenyl)-1-cyanopentan-3-yl)-1 H -indazol-4-yl)methanesulfonamide
• step B replacing ( E )-4-(4-amino-1 H -indazol-1-yl)-4-(4-chlorophenyl)hex-2-enenitrile with ( E )-4-(4-amino-1 H -indazol-1-yl)-4-(4-methoxyphenyl)hex-2-enenitrile, ( E )-4-(4-amino-1 H -indol-1-yl)-4-(4-chlorophenyl)hex-2-enenitrile, ( E )-4-(4-amino-1H-indazol-1-yl)-4-(4-(trifluoromethyl) phenyl)hex-2-enenitrile, ( E )-4-(4-amino-6-fluoro-1 H -indol-1-yl)-4-(4-chlorophenyl)hex-2-enenitrile, ( E )
• Step A N -(1-(3-(4-Chlorophenyl)-1-cyano-2-oxopentan-3-yl)-1 H -indol-4-yl)methane-sulfonamide
• Step A 2-(4-chlorophenyl)-2-(4-(methylsulfonamido)-1 H -indol-1-yl)butanoic acid
• Step B N -(2-chloroethyl)-2-(4-chlorophenyl)-2-(4-(methylsulfonamido)-1 H -indol-1-yl)butanamide
• Step A 2-(4-chlorophcnyl)- N -(1-(hydroxyimino)ethyl)-2-(4-(methylsulfonamido)-1 H -indol-1-yl)butanamide
• Step B N -(1-(1-(4-chlorophenyl)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl)-1 H -indol-4-yl)methanesulfonamide
• Step A tert -butyl 1-(3-(4-chlorophenyl)pent-1-yn-3-yl)-1 H -indol-4-ylcarbamate
• Step B tert -butyl 1-(1-(4-chlorophenyl)-1-(2 H -1,2,3-triazol-4-yl)propyl)-1 H -indol-4-ylcarbamate
• Step C tert -butyl 1-(1-(4-chlorophenyl)-1-(2-ethyl-2 H -1,2,3-triazol-4-yl)propyl)-1 H -indol-4-ylcarbamate
• Step D 1-(1-(4-chlorophenyl)-1-(2-ethyl-2 H -1,2,3-triazol-4-yl)propyl)-1 H -indol-4-amine
• step G Using the same procedure described for the preparation of Example 14, step G but replacing the 2-(4-( tert -butoxycarbonylamino)-6-fluoro-1 H -indol-1-yl)-2-(4-chlorophenyl)acetic acid with tert -butyl 1-(1-(4-chlorophenyl)-1-(2-ethyl-2 H -1,2,3-triazol-4-yl)propyl)-1 H -indol-4-ylcarbamate gave the title compound.
• Step E N -(1-(1-(4-chlorophenyl)-1-(2-ethyl-2 H -1,2,3-triazol-4-yl)propyl)-1 H -indol-4-yl)methanesulfonamide (Compound 152)
• step K Using the same procedure described for the preparation of Example 14, step K but replacing the methyl 2-(4-amino-6-fluoro-1 H -indol-1-yl)-2-(4-chlorophenyl)butanoate with 1-(1-(4-chlorophenyl)-1-(2-ethyl-2 H -1,2,3-triazol-4-yl)propyl)-1 H -indol-4-amine gave the title compound.
• Step A methyl 2-(4-chlorophenyl)-2-(4-formyl-1 H -indol-1-yl)acetate
• Step B methyl 2-(4-chlorophenyl)-2-(4-formyl-1 H -indol-1-yl)butanoate
• Step C ( E )-methyl 2-(4-chlorophenyl)-2-(4-(2-(methylsulfonyl)vinyl)-1 H -indol-1-yl)butanoate
• Step D methyl 2-(4-chlorophenyl)-2-(4-(2-(methylsulfonyl)ethyl)-1 H -indol-1-yl) butanoate
• Step A tert -butyl 1-(1-(4-chlorophenyl)-1-(1-hydroxycyclopropyl)propyl)-1 H -indol-4-ylcarbamate
• Step B 1-(1-(4-amino-1 H- indol-1-yl)-1-(4-chlorophenyl)propyl)cyclopropanol
• Step C N -(1-(1-(4-chlorophenyl)-1-(1-hydroxycyclopropyl(propyl)-1 H -indol-4-yl) methane sulfonamide
• Step A methyl 4-(4-chlorophenyl)-4-(4-( N -((2-(trimethylsilyl)ethoxy)methyl) methyl sulfonamido)-1 H- indol-1-yl)hex-2-ynoate
• Step B 4-(4-chlorophenyl)-4-(4-( N -((2-(trimethylsilyl)ethoxy)methyl)methylsulfonamido)-1 H- indol-1-yl)hex-2-ynoic acid
• Step C 4-(4-chlorophenyl)-4-(4-( N -((2-(trimethylsilyl)ethoxy)methyl)methylsulfonamido)-1 H- indol-1-yl)hex-2-ynamide
• Step D N -(1-(3-(4-chlorophenyl)-1-cyanopent-1-yn-3-yl)-1 H -indol-4-yl)- N -((2-(trimethyl silyl)ethoxy)methyl)methanesulfonamide
• Step E N -(1-(3-(4-chlorophenyl)-1-cyanopent-1-yn-3-yl)-1 H -indol-4-yl)methanesulfonamide
• Step A methyl 2-(4-( tert -butoxycarbonylamino)-1 H -indol-1-yl)-2-(4-chlorophenyl)-4-fluorobutanoate
• Step B methyl 2-(4-amino-1 H -indol-1-yl)-2-(4-chlorophenyl)-4-fluorobutanoate
• Step C methyl 2-(4-chlorophenyl)-4-fluoro-2-(4-(methylsulfonamido)-1 H -indol-1-yl)butanoate
• Step A 2-(4-(( tert -butoxycarbonyl)amino)-1 H -indazol-1-yl)-2-(4-chlorophenyl)butanoic acid
• Step B ethyl 2-amino-2-(((2-(4-(( tert -butoxycarbonyl)amino)-1 H -indazol-1-yl)-2-(4-chlorophenyl)butanoyl)oxy)imino)acetate
• Step C ethyl 5-(1-(4-(( tert -butoxycarbonyl)amino)-1 H -indazol-1-yl)-1-(4-chlorophenyl)propyl)-1,2,4-oxadiazole-3-carboxylate
• Step D ethyl 5-(1-(4-amino-1 H -indazol-1-yl)-1-(4-chlorophenyl(propyl)-1,2,4-oxadiazole-3-carboxylate
• Step E ethyl 5-(1-(4-chlorophenyl)-1-(4-(methylsulfonamido)-1 H- indazol-1-yl)propyl)-1,2,4-oxadiazole-3-carboxylate
• Step F 5-(1-(4-chlorophenyl)-1-(4-(methylsulfonamido)-1 H -indazol-1-yl)propyl)-1,2,4-oxadiazole-3-carboxamide
• Step A methyl 2-(4-( tert -butoxycarbonylamino)-1 H -indazol-1-yl)-2-(4-chlorophenyl)-4,4,4-trifluorobutanoate
• Step B tert -butyl 1-(2-(4-chlorophenyl)-4,4,4-trifluoro-1-hydroxybutan-2-yl)-1 H -indazol-4-ylcarbamate
• Step C tert -butyl 1-(2-(4-chlorophenyl)-4,4,4-trifluoro-1-oxobutan-2-yl)-1 H -indazol-4-ylcarbamate
• Step D tert -butyl 1-(3-(4-chlorophenyl)-5,5,5-trifluoropent-1-yn-3-yl)-1 H- indazol-4-ylcarbamate
• Step E tert -butyl 1-(3-(4-chlorophenyl)-1,1,1-trifluoropentan-3-yl)-1 H -indazol-4-ylcarbamate
• Step F 1-(3-(4-chlorophenyl)-1,1,1-trifluoropentan-3-yl)-1 H -indazol-4-amine
• Step G N -(1-(3-(4-chlorophenyl)-1,1,1-trifluoropentan-3-yl)-1 H -indazol-4-yl)methane sulfonamide
• Step A 4- tert -butyl 1-methyl 2-(4-( tert -butoxycarbonylamino)-1 H -indol-1-yl)-2-(4-chlorophenyl)succinate
• Step B 4- tert -butoxy-2-(4-( tert -butoxycarbonylamino)-1 H -indol-1-yl)-2-(4-chlorophenyl)-4-oxobutanoic acid
• Step C tert -Butyl 3-(4-( tert -butoxycarbonylamino)-1 H -indol-1-yl)-3-(4-chlorophenyl)-4-hydroxybutanoate
• Step D tert -butyl 3-(4-( tert -butoxycarbonylamino)-1 H -indol-1-yl)-3-(4-chlorophenyl)-4-oxobutanoate
• Step E tert -Butyl 3-(4-( tert -Butoxycarbonylamino)-1 H -indol-1-yl)-3-(4-chlorophenyl)pent-4-nyoate
• Step F tert -Butyl 3-(4-( tert -butoxycarbonylamino)-1 H -indol-1-yl)-3-(4-chlorophenyl) pentanoate
• Step G Methyl 3-(4-amino-1 H -indol-1-yl)-3-(4-chlorophenyl)pentanoate
• Step H Methyl 3-(4-chlorophenyl)-3-(4-(methylsulfonamido)-1 H -indol-1-yl)pentanoate
• Step I N -(1-(3-(4-Chlorophenyl)-1-hydroxypentan-3-yl-1 H -indol-4-yl)methanesulfonamide
• Step A N -(1-(3-(4-Chlorophenyl)-1-fluoropentan-3-yl)-1 H -indol-4-yl)methanesulfonamide
• Step A 3-(4-Chlorophenyl)-3-(4-(methylsulfonamido)-1 H -indol-1-yl)pentyl methanesulfonate
• Step A N -(1-(3-(4-Chlorophenyl)-1-methoxypentan-3-yl)-1 H -indol-4-yl)methanesulfonamide
• Step A tert -butyl 1-(3-(4-chlorophenyl)pent-1-yn-3-yl)-1 H -indol-4-ylcarbamate
• Step B methyl 4-(4-( tert -butoxycarbonylamino)-1 H -indol-1-yl)-4-(4-chlorophenyl)hex-2-ynoate
• Step C methyl 4-(4-( tert -butoxycarbonylamino)-1 H -indol-1-yl)-4-(4-chlorophenyl)hexanoate
• Step D methyl 4-(4-amino-1 H -indol-1-yl)-4-(4-chlorophenyl)hexanoate
• Step E methyl 4-(4-amino-1 H -indol-1-yl)-4-(4-chlorophenyl)hexanoate
• step A using tert-butyl (1-(2-(4-chlorophenyl)-1-oxobutan-2-yl)-1 H -indazol-4-yl)carbamate, compound 168 of Table 41 was obtained.
• Step A N -(1-(3-(4-chlorophenyl)-6-hydroxyhexan-3-yl)-1 H -indol-4-yl)methanesulfonamide
• Step A N -(1-(3-(4-chlorophcnyl)-6-nuorohexan-3-yl)-1 H -indol-4-yl)methanesulfonamide
• Step A ( E )-methyl 4-(4-amino-1 H -indazol-1-yl)-4-(4-chlorophenyl)hex-2-enoate
• Step B ( E )-methyl 4-(4-chlorophenyl)-4-(4-(methylsulfonamido)-1H-indazol-1-yl)hex-2-enoate
• Step A N-(1-(3-(4-chlorophenyl)-6-oxoheptan-3-yl)-1 H -indazol-4-yl)methanesulfonamide
• Step A tert -butyl (1-(1-(4-chlorophenyl)-1-(oxiran-2-yl)propyl)-1 H -indol-4-yl)carbamate
• Step B 3-(4-amino-1 H -indol-1-yl)-3-(4-chlorophenyl)-1-methoxypentan-2-ol
• Step C N- (1-(3-(4-chlorophenyl)-2-hydroxy-1-methoxypentan-3-yl)-1H indol-4-yl)methane sulfonamide
• Step A tert -butyl 1-(3-(4-chlorophenyl)pentan-3-yl)-1 H -indol-4-ylcarbamate
• Step B 1-(3-(4-chlorophenyl)pentan-3-yl)-1 H -indol-4-amine
• Step C N-(1-(3-(4-chlorophenyl)pentan-3-yl)-1 H -indol-4-yl)methanesulfonamide
• Step A tert -butyl 1-(3-(4-chlorophenyl)pent-1-en-3-yl)-1 H -indol-4-ylcarbamate
• Step B 1-(3-(4-chlorophenyl)pent-1-en-3-yl)-1 H -indol-4-amine
• Step C N -(1-(3-(4-chlorophenyl)pent-1-en-3-yl)-1H-indol-4-yl)methanesulfonamide
• Step A N -(1-(3-(4-chlorophenyl)-2-(hydroxyimino)entan-3-yl)-1 H -indol-4-yl)methane sulfonamide
• Step B N-(1-(2-amino-3-(4-chlorophenyl)pentan-3-yl)-1 H -indol-4-yl)methanesulfonamide
• step A Using the procedure described in Example 39, but in step A replacing N -(1-(3-(4-chlorophenyl)-2-oxopentan-3-yl)-1 H -indol-4-yl)methanesulfonamide with N -(1-(2-(4-chlorophenyl)-1-oxobutan-2-yl)-1 H -indol-4-yl)methanesulfonamide, compound 177 of Table 49 was prepared.
• Step A methyl 2-(4-chlorophenyl)-2-(4-(ethylsulfonamido)-1 H -indol-1-yl)butanoate
• Ethanesulfonyl chloride (0.26 g, 2 mmol) was added to a stirred solution of methyl 2-(4-amino-1 H -indol-1-yl)-2-(4-chlorophenyl)butanoate (0.58 g, 1.7 mmol), as described in Example 3 Step B, and 4-methylmorpholine (0.25 g, 2.5 mmol) in DCM (8 mL) at 0 °C. After 30 min, an additional portion of ethanesulfonyl chloride (0.1 g, 1 mmol) was added. After 1 h, the reaction mixture was partitioned between DCM and saturated aqueous ammonium chloride.
• Step B 2-(4-chlorophenyl)-2-(4-(ethylsulfonamido)-1 H -indol-1-yl)butanamide
• Enantiomer A and enantiomer B were obtained by the below chiral separation conditions:
• Step C N -(1-(1-(4-chlorophenyl)-1-cyanopropyl)-1 H -indol-4-yl)ethanesulfonamide
• Step A N- (1-(1-(4-chlorophenyl)-1-cyanopropyl)-1 H -indol-4-yl)methanesulfonamide
• Step B N- (1-(1-(4-chlorophenyl)-1-(2 H -tetrazol-5-yl)propyl)-1 H -indol-4yl)methane sulfonamide
• Step C N-(1-(1-(4-chlorophenyl)-1-(2-ethyl-2 H -tetrazol-5-yl)propyl)-1 H -indol-4-yl)methane sulfonamide
• Step A N -(1-(3-(4-chlorophenyl)pent-1-yn-3-yl)-1 H -indol-4-yl)-N-((2-(trimethylsilyl)ethoxy)methyl)methanesulfonamide
• Example 32 Step A The title compound was prepared according to the procedure in Example 32 Step A using N- (1-(2-(4-chlorophenyl)-1-oxobutan-2-yl)-1 H -indazol-4-yl)- N -((2-(trimethylsilyl)ethoxy)methyl) methane sulfonamide(enantiomer A), as described in Example 20 Step E, as starting material.
• Step B N -(1-(3-(4-chlorophenyl)-6,6,6-trifluorohex-4-yn-3-yl)-1 H -indol-4-yl)- N -((2-(trimethylsilyl)ethoxy)methyl)methanesulfonamide
• a three-neck round-bottom flask was charged with CuI (38 mg, 0.2 mmol), Phen ⁇ H 2 O (40 mg, 0.2 mmol), KF (58 mg, 1.0 mmol) and stirring bar.
• the flask was dried at 130 °C in vacuo for 3 h. After cooling to RT, the flask was backfilled with air and TMSCF 3 (142 mg, 1.0 mmol), DMF (2 mL) was added. Then the flask was heated to 130 °C for 30 min.
• Step C N -(1-(3-(4-chlorophenyl)-6,6,6-trifluorohexan-3-yl)-1 H -indol-4-yl)- N -((2-(trimethylsilyl) ethoxy)methyl)methanesulfonamide
• Step D N -(1-(3-(4-chlorophenyl)-6,6,6-trifluorohexan-3-yl)-1 H -indol-4-yl)methanesulfonamide
• the activity of the compounds of the present invention regarding mineralocorticoid receptor antagonism can be evaluated using the following assay.
• the human MR NH Pro assay is a commercially available PathHunterTM Protein :Protein interaction assay (DiscoveRx; http://www.discoverx.com/nhrs/prod-nhrs.php) that measures the ability of compounds to antagonize full-length human Mineralocorticoid Receptor (MR) binding to a coactivator peptide.
• PathHunterTM Protein :Protein interaction assay (DiscoveRx; http://www.discoverx.com/nhrs/prod-nhrs.php) that measures the ability of compounds to antagonize full-length human Mineralocorticoid Receptor (MR) binding to a coactivator peptide.
• PathHunterTM CHO-K1 cells that overexpress human MR (Cat #93-0456C2, Lot No: 09B0913) were cultured in growth media (F12K w/Glutamine and phenol red (Gibco 11765-047) supplemented with 10% HI FBS (Gibco 16000); 0.25mg/ml Hygromycin in PBS (Invitrogen 10687-010, 50mg/ml); 100 I.U./mL and 100 ⁇ g/mL Pen/Strep (Gibco 15140-122); 0.6mg/mL Geneticin).
• Compounds were assessed for MR antagonist activity by incubating the cells with a titrating dose of compound in F12K w/Glutamine and phenol red culture media (Invitrogen 11765-047) supplemented with 1 % Charcoal/Dextran Treated FBS (Hyclone #SH30068.01) and aldosterone (0.3 nM) for 6 hours at 37°C. Cells were then treated with DiscoveRx detection reagent for 1 hour at room temperature and read using an Envision luminescence plate reader. % activity was measured relative to cells treated with aldosterone alone and IC 50 values were calculated using ADA software.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Endocrinology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Steroid Compounds (AREA)
• Indole Compounds (AREA)

Applications Claiming Priority (2)

Publications (3)

Family

ID=46515166

Family Applications (1)

Country Status (11)

Families Citing this family (20)

Family Cites Families (51)

• 2012
  • 2012-01-19 MX MX2013008431A patent/MX351305B/es active IP Right Grant
  • 2012-01-19 EP EP12736795.1A patent/EP2665707B1/en active Active
  • 2012-01-19 KR KR1020137019134A patent/KR20140009291A/ko not_active Ceased
  • 2012-01-19 ES ES12736795.1T patent/ES2618812T3/es active Active
  • 2012-01-19 AU AU2012208837A patent/AU2012208837B2/en not_active Ceased
  • 2012-01-19 RU RU2013138569/04A patent/RU2598842C2/ru not_active IP Right Cessation
  • 2012-01-19 WO PCT/CN2012/070597 patent/WO2012097744A1/en active Application Filing
  • 2012-01-19 US US13/979,875 patent/US8933113B2/en active Active
  • 2012-01-19 JP JP2013549707A patent/JP6078004B2/ja not_active Expired - Fee Related
  • 2012-01-19 CN CN201280005921.6A patent/CN103384661B/zh not_active Expired - Fee Related
  • 2012-01-19 CA CA2824344A patent/CA2824344A1/en not_active Abandoned
• 2014
  • 2014-12-02 US US14/557,980 patent/US9403807B2/en active Active

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events